CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 108 enrolled
Drug / intervention
MP-424 (generic name:Telaprevir) +2 moredrug
Likely dose
MP-424 (generic name:Telaprevir) 750mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01466192
NCT01466192Phase 3Completed
CompareCT.gov

A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin in Subjects With Genotype 2 Hepatitis C, Who Relapsed After Previous Treatment

Tanabe Pharma Corporation·interventional·Posted Nov 7, 2011·Updated Jan 6, 2026

In Brief

A Phase 3 clinical trial evaluating MP-424 (generic name:Telaprevir), Ribavirin, and 1 other intervention for Chronic Hepatitis C. Completed, enrolled 108 participants across 1 site.

Detailed Summary

This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and Ribavirin (RBV) in patients with genotype 2 hepatitis C, who relapsed after previous treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 7, 2011
Enrollment StartMay 1, 2012
Primary CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 14.7 years ago

Interventions

MP-424 (generic name:Telaprevir)drug

750mg q8h for 12 weeks

Ribavirindrug

400 - 1000 mg/day based on body weight for 24 weeks

Peginterferon alfa-2bdrug

1.5mcg/kg/week for 24 weeks